Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-05T16:54:39.683Z Has data issue: false hasContentIssue false
  • English
  • Français

Combined continuous hormone replacement therapy: an update

Published online by Cambridge University Press:  03 June 2009

Laurence C Udoff  and
Eli Y Adashi
Laurence C Udoff
Affiliation:
Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah 84132, USA
Eli Y Adashi*
Affiliation:
Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah 84132, USA
*
Department of Obstetrics and Gynecology, University of Utah, Suite 2B200, 50 North Medical Drive, Salt Lake City, Utah 84132, USA.
Get access Rights & Permissions [Opens in a new window]

Extract

A growing body of information now supports the theory that oestrogen replacement therapy can substantially eliminate or attenuate the complications incurred as a result of the menopause. In particular, data support the claim that oestrogen replacement therapy for postmenopausal women is associated with the relief of vasomotor symptoms, the prevention of osteoporosis and urogenital atrophy, a lowering of cardiovascular morbidity and mortality, improved cognitive functioning, and a lower incidence of Alzheimer's disease.

Type
Research Article
Information
Reproductive Medicine Review , Volume 6 , Issue 1 , March 1997 , pp. 1 - 22
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Upton, GV. Therapeutic considerations in the management of the climacteric. J Reprod Med 1984; 29: 71–80.Google ScholarPubMed
2Session, DR, Kelly, AC, Jewelewicz, R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril 1993; 59: 277–84.CrossRefGoogle ScholarPubMed
3Mishell, DR. Estrogen replacement therapy: an overview. Am J Obstet Gynecol 1989; 161: 1825–27.Google Scholar
4Cauley, JA, Cummings, SR, Black, DM, Mascioli, SR, Seeley, DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163: 1338–44.CrossRefGoogle ScholarPubMed
5Paganini-Hill, A, Henderson, VW. Estrogen replacement therapy and the risk of Alzheimer's disease. Arch Intern Med 1996; 156: 2213–17.CrossRefGoogle Scholar
6Utian, WG, Schiff, I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1: 39.Google Scholar
7Ravnikar, VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332.CrossRefGoogle ScholarPubMed
8Hemminiki, E, Brambilla, DJ, McKinlay, SM, Posner, JG. Use of estrogens among middle aged Massachusetts women. DICP 1991; 25: 418–23.CrossRefGoogle Scholar
9Wren, BG, Brown, L. Compliance with hormonal replacement therapy. Maturitas 1991; 13: 17–21.Google Scholar
10Flowers, CE, Wilborn, WH, Hyde, BM. Mechanisms of uterine bleeding in postmenopausal women receiving estrogen alone or with a progestin. Obstet Gynecol 1985; 61: 135–43.Google Scholar
11Marslew, U, Riis, BJ, Christiansen, C. Progestogens: therapeutic and adverse effects in early postmenopausal women. Maturitas 1991; 13: 7–16.CrossRefGoogle Scholar
12Whitehead, MI, Hillard, TC, Crook, D. The role and use of progestogens. Obstet Gynecol 1990; 75: 559–76.Google Scholar
13Nachtigall, LE. Enhancing patient compliance with hormonal replacement therapy at menopause. Obstet Gynecol 1990; 4(S): 77s–80s.Google Scholar
14March, MS, Whitehead, MI. The practicalities of hormone replacement. Balliéres Clin Endocrinol Metab 1993; 7: 183–202.Google Scholar
15Birkenfeld, A, Kase, NG. Menopause medicine: current treatment options and trends. Compr Ther 1991; 17: 36–45.Google ScholarPubMed
16Lobo, RA, Pickar, JH, Wild, R, Walsch, B. Hirvonen for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987–95.Google Scholar
17Grey, AB, Cundy, TF, Reid, IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 1994; 40: 671.Google Scholar
18Staland, B. Continuous treatment with a combination of estrogen and gestagen. A way of avoiding endometrial stimulation. Acta Obstet Gynecol Scand Suppl 1985; 130: 29.Google Scholar
19Magos, AL, Brincat, M, Studd, JWW et al. Amenorrhea and endometrial atrophy with continuous oral estrogen and progesterone therapy in postmenopausal women. Obstet Gynecol 1985; 65: 496.Google Scholar
20Sporrong, T, Hellgren, M, Samsioe, G et al. Comparison of four continuously administered progestogen plus estradiol combinations for climacteric complaints. Br J Obstet Gynecol 1988; 95: 1042.Google Scholar
21Weinstein, L, Bewtra, C, Gallagher, JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162: 153.CrossRefGoogle ScholarPubMed
22Williams, SR, Frenchek, B, Spsroff, L et al. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol 1990; 162: 438.Google Scholar
23Hillard, TC, Siddle, NC, Whitehead, MI et al. Continuous combined conjugated equine estrogenprogestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histological diagnosis. Am J Obstet Gynecol 1992; 167: 1.CrossRefGoogle Scholar
24Obel, EB, Munk-Jensen, N, Svenstrup, B et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16: 13.CrossRefGoogle ScholarPubMed
25Rauch, U, Taubert, HD. Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable doses. A preliminary study. Maturitas 1993; 17: 123.CrossRefGoogle Scholar
26MacLennan, AH, MacLennan, A, Wenzel, S et al. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomized trial. Med J Aust 1993; 159: 102.Google Scholar
27Marsh, MS, Crook, D, Whitcroft, SIJ et al. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994; 83: 19.Google ScholarPubMed
28Archer, DF, Pickar, JH, Bottiglioni, F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686.Google ScholarPubMed
29Munk-Jensen, N, Ulrich, LG, Obel, EB et al. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoproteins in a two year placebo controlled trial. Am J Obstet Gynecol 1994; 171: 132.CrossRefGoogle Scholar
30Voetberg, GA, Netelenbos, JC, Kenemans, P et al. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994; 79: 1465.Google ScholarPubMed
31Spaulding, CB. Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement. Fertil Steril 1994; 62: 1181.Google Scholar
32The Postmenopausal Estrogen/Progestin Interventions Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199.Google Scholar
33Clisham, PR, deZiegler, D, Lozano, K et al. Comparison of sequential versus continuous estrogen and progestin replacement therapy in post-menopausal women. Obstet Gynecol 1991; 77: 241.CrossRefGoogle Scholar
34Luciano, AA, DeSouza, MJ, Roy, MP et al. Evaluation of low dose estrogen and progestin therapy in post-menopausal women. J Reprod Med 1993; 38: 207.Google Scholar
35Weinstein, L. Efficacy of a continuous estrogenprogestin regimen in the menopausal patient. Obstet Gynecol 1987; 69: 929.Google ScholarPubMed
36Kable, WT, Gallagher, JC, Nachtigal, L et al. Lipid changes after hormone replacement therapy for menopause. J Reprod Med 1990; 35: 512.Google Scholar
37Nang, SL, Webster, MA, Wren, BG. Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy. A study of bleeding pattern, endometrial response, serum lipid and bone density changes. Aust NZ J Obstet Gynaecol 1995; 35: 92.Google Scholar
38Yancey, MK, Stone, IK, Hannan, CJ. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertil Steril 1990; 54: 778.Google Scholar
39Andersson, K, Mattsson, L, Rybo, G et al. Intrauterine release of levonorgestrel. A new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963.Google ScholarPubMed
40Raudaskoski, TH, Lahti, El, Kauppila, AJ et al. Transdermal estrogen with a levonorgestrelreleasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114.CrossRefGoogle ScholarPubMed
41Marslew, U, Riis, BJ, Christiansen, C. Bleeding patterns during continuous combined estrogen progestogen therapy. Am J Obstet Gynecol 1991; 164: 1163.CrossRefGoogle ScholarPubMed
42Keller, PJ, Holtz, E, Imthrun, B. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. Maturitas 1992; 15: 195.Google Scholar
43Marslew, U, Overgaard, K, Riis, BJ et al. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: longterm effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992; 79: 202.Google Scholar
44Hargrove, JT, Maxson, WS, Wentz, AL et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73: 606.Google ScholarPubMed
45Prough, SG, Aksel, S, Wiebe, RH et al. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987; 157: 1449.Google Scholar
46Luciano, AA, Turksoy, RN, Carleo, J et al. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet Gynecol 1988; 71: 39.Google Scholar
47Leather, AT, Savvas, M, Studd, JWW. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1088.Google ScholarPubMed
48Holst, J, Cajander, S, von Schoultz, B. Endometrial effects of a continuous percutaneous oestrogen/low-dose oral progestogen regimen for climacteric complaints. Maturitas 1987; 9: 63.CrossRefGoogle ScholarPubMed
49Oosterbaan, HP, van Burren, AJHAM, Schram, JHN et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995; 21: 211.CrossRefGoogle ScholarPubMed
50Wolfe, BM, Huff, MW. Effects of continuous lowdosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women. Metabolism 1995; 44: 410.Google Scholar
51Christiansen, C, Riis, BJ. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins and bleeding pattern. Br J Obstet Gynaecol 1990; 97: 1087–92.CrossRefGoogle ScholarPubMed
52Christiansen, C, Riis, BJ. 17-β estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 4: 836.Google Scholar
53Fuleihan, G, Brown, EM, Curtis, K. Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism. Arch Mem Med 1992; 152: 1904.Google Scholar
54Riis, BJ, Hohansen, J, Christiansen, C. Continuous oestrogen-progestogen treatment and bone metabolism in postmenopausal women. Maturitas 1988; 10: 51.Google Scholar
55Bewtra, C, Kable, WT, Gallagher, JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med 1988; 32: 205–8.Google Scholar
56Farish, E, Fletcher, CD, Dagen, MM. Lipoprotein and apolipoprotein levels in post-menopausal women on continuous oestrogen/progestogen therapy. Br J Obstet Gynaecol 1989; 96: 358–64.Google Scholar
57Mattson, LA, Callberg, G, Samsioe, G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric patients. Maturitas 1982; 4: 95–102.CrossRefGoogle Scholar
58Jensen, J, Riis, BJ, Strom, V, Christiansen, C. Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 1987; 97: 130.Google Scholar
59Hawthorne, RJS. The endometrial status of women on long-term continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1991; 98: 939.CrossRefGoogle Scholar
60Cano, A, Fernandes, H, Serrano, S, Mahiques, P. Effects on continuous oestradiolmedroxyprogesterone administration on plasma lipids and lipoproteins. Maturitas 1991; 13: 35.Google Scholar
61Metka, M, Hanes, V, Heytmanek, G. Hormone replacement therapy: lipid responses to continuous combined oestrogen and progestogen vs. oestrogen monotherapy. Maturitas 1992; 15: 53.CrossRefGoogle Scholar
62Suhonen, SP, Holmstrom, T, Alonen, HO, Lahteenmake, P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63: 36.Google Scholar
63Denke, MA. Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholestrolemic postmenopausal women. Am J Med 1995; 99: 29.Google Scholar
64Suvanto-Luukkonen, E, Sundstrom, H, Penttinen, J, Kauppila, A, Rutanen, EM. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995; 22: 255.Google Scholar
65Wollter-Svensson, LO, Stadberg, E, Andersson, K, Mattsson, LA, Odlind, V, Persson, I. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas 1995; 22: 199.CrossRefGoogle ScholarPubMed
66Ainmelk, Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril 1996; 66: 962.Google Scholar
67Speroff, L, Rowan, J, Symons, J, Genant, H, Wilborn, W. The comparative effect on bone density, endometrium and lipids on continuous hormones as replacement therapy (CHART Study). JAMA 196; 276: 1397.Google Scholar
68Farish, E, Spowart, K, Barnes, JF, Fletcher, CD, Calder, A, Brown, A, Hart, DM. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions. Atherosclerosis 1996; 126: 77.Google Scholar
69Grey, A, Cundy, T, Evans, M, Reid, I. Medroxyprogesterone acetate enhances the spinal bone mineral density response to estrogen in late postmenopausal women. Clin Endocrinol 196; 44: 293–96.Google Scholar
70Kalogirou, D, Antoniou, G, Karakitsos, P, Kalogirou, O, Antoniou, D, Giannikos, L. A comparative study of the effects of an estradiolreleasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. Int J Fertil 1996; 41: 522–27.Google Scholar
71Tilly-Kiesi, M, Lappi, M, Puolakka, J, Luotola, H, Pyorala, T, Taskinen, MR. Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on lowdensity lipoprotein subclasses. Eur J Clin Invest 1996; 26: 1125.CrossRefGoogle ScholarPubMed
72Eiken, P, Kolthoff, N, Nielsen, SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 19: 191.–193S.Google Scholar
73Ettinger, B, Li, D, Klein, R. Continuation of postmenopausal hormone replacement therapy; comparison of cyclic versus continuous combined schedules. Menopause 1996; 3: 185–89.CrossRefGoogle Scholar
74Kupperman, HS. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Endocrinol Metab 1953; 13: 688–703.Google Scholar
75Henderson, BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161: 1859.CrossRefGoogle ScholarPubMed
76Harlap, S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992; 166: 1986.Google Scholar
77Woodruff, JD, Pickar, JH for The Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213.Google Scholar
78The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996; 275: 370.Google Scholar
79Kurman, RJ, Kaminski, PF, Norris, HJ. The behavior of endometrial hyperplasia: a long term study of ‘untreated’ hyperplasia in 170 patients. Cancer 1985; 56: 403.Google Scholar
80Gelfand, MM, Ferenczy, A. A prospective 1-year study of estrogen and progestin in postmenopausal women. Obstet Gynecol 1989; 74: 398.Google ScholarPubMed
81Udoff, L, Langenberg, P, Adashi, EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 306.Google Scholar
82Bush, TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Kerenman, SG (ed) The menopause: biological and clinical consequences of ovarian failure; evolution and management. Serono Symposia, Norwell, Mass., 1990, p. 211.Google Scholar
83Stampfer, MJ, Colditz, GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47.Google Scholar
84Grady, D, Rubin, SM, Petitti, DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016.Google Scholar
85Shahar, E, Folsom, AR, Soloman, W et al. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996; 96: 1970.Google Scholar
86Gebara, OL, Mittleman, MA, Sutherland, P, Lipinska, I. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952.CrossRefGoogle ScholarPubMed
87White, RE, Darkow, DJ, Lang, JL. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995; 77: 936.CrossRefGoogle ScholarPubMed
88Stevenson, JL. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995; 49: 87.Google Scholar
89Tikkanen, MK, Kuusi, T, Nikkila, EA, Sipinen, S. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins: a review. Maturitas 1986; 8: 7.Google Scholar
90Newnham, HH. Oestrogens and atherosclerotic vascular disease: lipid factors. Ballieres Clin Endocrinol Metab 1993; 7: 61.Google Scholar
91Psaty, BM, Hackbert, SR, Atkins, D, Lemaitre, R et al. The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women. Arch Intern Med 1994; 154: 1333.Google Scholar
92Falkeborn, M, Persson, I, Adami, HO et al. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821.CrossRefGoogle Scholar
93Grodstein, F, Stampfer, MJ, Manson, JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 336: 453.Google Scholar
94Andersson, K, Stadberg, E, Mattsson, LA, Rybo, G. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women-effects on lipid metabolism during 12 months of treatment. Int J Fertil 1996; 41: 476.Google ScholarPubMed
95Taskinen, MR, Puolakka, J, Pyorala, T, Luotola, H, Bjorn, M, Kaariainen, J, Lahdenpera, S, Ehnholm, C. Hormone replacement therapy lowers plasma Lp(a) concentrations. Arterioscler Thrombo Vase Biol 1996; 16: 1215–21.Google Scholar
96Lobo, RA. Effects of hormonal replacement on lipids and lipoproteins in post-menopausal women. J Clin Endocrinol Metab 1991; 73: 925–30.Google Scholar
97Udoff, L, Adashi, EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 869.Google Scholar
98Bass, KM, Newschaffer, CJ, Klag, MJ, Bush, TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153: 2209–16.Google Scholar
99Glueck, CJ, Lang, J, Hamer, T, Tracy, T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123: 59–64.Google ScholarPubMed
100Tikkanen, MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996; 23: 209–16.CrossRefGoogle ScholarPubMed
101Stevenson, JC, Crook, D, Godsland, IF et al. Oral versus transdermal hormone replacement therapy. Int J Fertil 1993; 38(suppl): 30–35.Google Scholar
102Maher, VMG, Brown, BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229–235.Google Scholar
103Berglund, L. Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 1995; 6: 48–56.Google Scholar
104Meilhahn, EN, Kuller, LH, Matthews, KA, Stein, EA. Lp(a) concentrations in pre- and postmenopausal women over time: the Healthy Women Study. Circulation 1991; 84(suppl): 11–2170.Google Scholar
105Andersson, B, Mattson, LA, Hahn, L, Maria, P, Lapidus, L, Holm, G, Bengtsson, BA, Bjorntorp, P. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitis. J Clin Endocrinol Metab 1997; 82: 638–43.Google Scholar
106Wilcox, JG, Hwany, J, Hodis, HN, Sevanian, A, Stomczyk, FZ, Lobo, RA. Cardioprotective effects of individual conjugated equine estrogen through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 1997; 67: 57–62.Google Scholar
107Lindheim, SR, Presser, L, Ditkoff, E, Vijod, MA, Staczyk, FZ, Lobo, RA. A possible bimodal effect of estrogen in insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664–67.Google Scholar
108Wagner, JD, Martino, MA, Jayo, MJ, Anthony, MS, Clarkson, JB, Cefalu, WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 1996; 45: 1245–62.CrossRefGoogle ScholarPubMed
109Daly, E, Vesky, MP, Hawkins, MM, Carson, JC, Gough, P, Marsh, S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80.Google Scholar
110Jick, H, Derby, LE, Myers, MW, Vasilakis, C, Newton, KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–87.Google Scholar
111Vanderbroucke, JP, Helmerhoest, FM. Risk of venous thrombosis with hormone replacement therapy. Lancet 1996; 348: 972.Google Scholar
112Simioni, P, Prandoni, P, Lensing, AW et al. The risk of recurrent venous thromboembolism in patients with an Arg-506- Glu mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399–403.Google Scholar
113Ericksen, EF, Kassem, M, Langdahl, B. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996; 19: 179.–183S.Google Scholar
114Pacifici, R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043–51.Google Scholar
115Whitehead, MI, Lobo, RA. Progestogen use in postmenopausal women. Consensus conference. Lancet; 2: 1243–44.Google Scholar
116The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 1996; 276: 1389–96.Google Scholar